EGFR and neoplasm: However, a recent bicentric prospective study [54] showed that aTAT of results (defined in that study as time from tumor sampling to initiation of EGFR-TKIs) was reduced by 12.5 calendar days when using the IdyllaTM EGFR Mutation Test versus NGS with a reported OPA of 96.4%.